ZM241385

ZM241385 is a selective antagonist for the human A3 adenosine receptor, a subtype of purinergic receptors that play a role in various physiological processes. It was developed as a tool compound to study the functions and mechanisms of the A3 receptor. The A3 receptor is widely expressed in many tissues, including the brain, heart, and immune cells, and is involved in inflammation, ischemia, and other pathological conditions.

ZM241385 has a high affinity for the A3 receptor, with a Ki value of approximately 1.4 nM, and exhibits selectivity over other adenosine receptor subtypes, such as A1, A2A, and A2B. The compound acts as a competitive antagonist, binding to the receptor and blocking the effects of adenosine, the endogenous ligand for the A3 receptor. This antagonistic activity makes ZM241385 useful for investigating the role of the A3 receptor in various biological processes and disease states.

In addition to its research applications, ZM241385 has also been studied for its potential therapeutic effects. For instance, it has been shown to have anti-inflammatory and neuroprotective properties in animal models of ischemia and neurodegeneration. However, further research is needed to fully understand the therapeutic potential of ZM241385 and to develop it into a clinically useful drug.

ZM241385 is typically used in in vitro studies, such as receptor binding assays and cell-based functional assays, to characterize the properties of the A3 receptor and to screen for new antagonists. It is also used in in vivo studies to investigate the physiological and pathological roles of the A3 receptor in animal models of disease. Overall, ZM241385 is a valuable tool compound for studying the A3 adenosine receptor and its potential as a therapeutic target.